Q32 Bio Inc. (QTTB): Total Liabilities
$19.76M
As of 2025-12-31
$9.96M
As of 2026-06-30
-26.9%
3-year compound annual growth
-21.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.76M | -77.2% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $86.66M | -26.9% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $118.53M | +134.8% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $50.49M | +20.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $42.07M | -37.9% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $67.74M | +30.1% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $52.06M | -17.0% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $62.74M | n/c | 2020-03-12, Balance as of period end |
| 2017-12-31 | $39.22M | n/a | 2019-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $104.11M | -14.8% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗